<p class="title">Pharma major Lupin on Monday said the US health regulator has issued three observations after inspection of its Tarapur facility in Maharashtra.</p>.<p class="bodytext">The inspection of Tarapur facility was carried out by the United States Food and Drug administration (USFDA) between September 16-20, 2019.</p>.<p class="bodytext">"The inspection at the Tarapur facility closed with three observations," Lupin said in a regulatory filing.</p>.<p class="bodytext">Lupin did not elaborate on the nature of the observations.</p>.<p class="bodytext">"The Company is confident of addressing them satisfactorily," the filing added.</p>.<p class="bodytext">Shares of Lupin were trading 3.52 per cent lower at Rs 729.50 apiece on BSE. </p>
<p class="title">Pharma major Lupin on Monday said the US health regulator has issued three observations after inspection of its Tarapur facility in Maharashtra.</p>.<p class="bodytext">The inspection of Tarapur facility was carried out by the United States Food and Drug administration (USFDA) between September 16-20, 2019.</p>.<p class="bodytext">"The inspection at the Tarapur facility closed with three observations," Lupin said in a regulatory filing.</p>.<p class="bodytext">Lupin did not elaborate on the nature of the observations.</p>.<p class="bodytext">"The Company is confident of addressing them satisfactorily," the filing added.</p>.<p class="bodytext">Shares of Lupin were trading 3.52 per cent lower at Rs 729.50 apiece on BSE. </p>